)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Emergent BioSolutions (EBS) investor relations material
Emergent BioSolutions Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary29 Oct, 2025
Executive summary
Q3 2025 performance exceeded expectations, with total revenues of $231.1M, net income of $51.2M, and strong operational execution under a multi-year transformation plan.
Year-to-date 2025 revenues were $594.2M, with net income of $107.2M and adjusted EBITDA of $193.9M, reflecting improved profitability and margin expansion.
Maintained leadership in naloxone and MCM products, with significant international expansion and contract wins.
Completed significant restructuring and divestitures, including the sale of RSDL® rights and the Baltimore-Bayview facility.
Raised full-year 2025 revenue and adjusted EBITDA guidance based on robust performance and market demand.
Financial highlights
Q3 2025 revenue was $231.1M, surpassing guidance but down 21% year-over-year due to divestitures.
Q3 net income was $51.2M; YTD net income reached $107.2M with EPS of $1.99.
Adjusted EBITDA for Q3 was $87.8M (38% margin); YTD adjusted EBITDA was $193.9M (33% margin).
Gross margin improved to 54% in Q3 (adjusted 61%); YTD gross margin was 48% (adjusted 57%).
Operating expenses for Q3 were $52M, down significantly year-over-year, with SG&A cut by roughly 50%.
Outlook and guidance
Full-year 2025 revenue guidance raised to $775M–$835M; adjusted EBITDA guidance increased to $195M–$210M.
Adjusted gross margin guidance set at 52%–54%, a 200 basis point improvement.
MCM product sales guidance set at $450M–$475M; commercial products, including naloxone, guided to $275M–$300M.
Management expects continued variability in quarterly results due to government contract timing.
Liquidity and capital resources are expected to be sufficient for at least the next twelve months.
International MCM growth: Is it sustainable?
Future capital deployment priorities?
Naloxone market growth sustainability?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Emergent BioSolutions earnings date
Q4 20255 Mar, 2026
Next Emergent BioSolutions earnings date
Q4 20255 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Emergent BioSolutions Inc. is a specialty pharmaceutical company that focuses on the development, manufacture and commercialization of vaccines and therapeutics. The Company's products consist of anthrax vaccine (BioThrax (Anthrax Vaccine Adsorbed)), the only Food and Drug Administration (FDA) approved vaccine for the prevention of anthrax infection; other vaccines in development, including Vaxchora for the prevention of cholera; NuThrax for the treatment of anthrax infection in combination with antibiotics; ACAM100, a smallpox vaccine for biodefense use, and AIGIV, a rabies vaccine candidate for pre- and post-exposure prophylaxis.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage